Index S&P 500
P/E 48.17
EPS (ttm) 7.58
Insider Own 0.55%
Shs Outstand 73.50M
Perf Week 1.27%
Market Cap 26.59B
Forward P/E 40.22
EPS next Y 9.08
Insider Trans -15.77%
Shs Float 72.44M
Perf Month -5.46%
Income 568.70M
PEG 7.01
EPS next Q 1.74
Inst Own 96.67%
Short Float 1.35%
Perf Quarter -4.20%
Sales 2.93B
P/S 9.08
EPS this Y -4.00%
Inst Trans -1.66%
Short Ratio 1.80
Perf Half Y 13.47%
Book/sh 36.72
P/B 9.94
EPS next Y 17.01%
ROA 15.53%
Short Interest 0.98M
Perf Year -0.93%
Cash/sh 8.26
P/C 44.18
EPS next 5Y 6.87%
ROE 20.84%
52W Range 310.42 - 415.73
Perf YTD 3.66%
Dividend Est. 0.74 (0.20%)
P/FCF 68.86
EPS past 5Y 23.49%
ROI 20.05%
52W High -12.20%
Beta 1.04
Dividend TTM 0.79 (0.22%)
Quick Ratio 1.95
Sales past 5Y 11.96%
Gross Margin 37.28%
52W Low 17.59%
ATR (14) 10.43
Dividend Ex-Date Jul 31, 2024
Current Ratio 2.61
EPS Y/Y TTM 3.48%
Oper. Margin 23.08%
RSI (14) 42.82
Volatility 3.15% 2.60%
Employees 10600
Debt/Eq 0.11
Sales Y/Y TTM 1.62%
Profit Margin 19.42%
Recom 1.91
Target Price 402.15
Option/Short Yes / Yes
LT Debt/Eq 0.06
EPS Q/Q -16.09%
Payout 9.90%
Rel Volume 0.82
Prev Close 368.46
Sales Surprise 3.69%
EPS Surprise 22.51%
Sales Q/Q -2.88%
Earnings Apr 25 BMO
Avg Volume 542.57K
Price 365.02
SMA20 -3.24%
SMA50 -3.24%
SMA200 -1.55%
Trades
Volume 447,307
Change -0.93%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-07-24 Upgrade
Jefferies
Hold → Buy
$323 → $536
Jun-16-23 Upgrade
BofA Securities
Neutral → Buy
$390 → $405
Apr-11-23 Upgrade
Stephens
Equal-Weight → Overweight
$330 → $400
Dec-14-22 Initiated
Deutsche Bank
Hold
$250
Nov-30-22 Initiated
UBS
Neutral
$250
Oct-28-22 Downgrade
BofA Securities
Buy → Neutral
$385 → $250
Nov-10-20 Initiated
KeyBanc Capital Markets
Overweight
$350
Oct-14-20 Initiated
Stephens
Equal-Weight
$300
Jul-21-20 Upgrade
BofA Securities
Neutral → Buy
$280
Apr-24-20 Upgrade
BofA/Merrill
Underperform → Neutral
$145 → $200
Dec-12-19 Downgrade
BofA/Merrill
Neutral → Underperform
Jul-26-19 Upgrade
BofA/Merrill
Underperform → Neutral
May-01-19 Downgrade
Jefferies
Buy → Hold
$122
Apr-23-19 Initiated
William Blair
Outperform
Apr-25-18 Downgrade
BofA/Merrill
Neutral → Underperform
Jan-24-18 Initiated
Goldman
Neutral
Oct-17-17 Downgrade
BofA/Merrill
Buy → Neutral
Oct-03-17 Initiated
Stephens
Equal-Weight
Sep-15-17 Upgrade
Jefferies
Hold → Buy
Oct-28-16 Upgrade
Wells Fargo
Market Perform → Outperform
Show Previous Ratings
Apr-30-24 09:19AM
06:00AM
Apr-29-24 07:40PM
Apr-27-24 01:07AM
Apr-26-24 11:34AM
11:07AM
Loading…
11:07AM
10:56AM
03:12AM
Apr-25-24 10:31AM
09:12AM
08:34AM
07:10AM
07:02AM
06:43AM
06:08AM
(Associated Press Finance)
06:00AM
Loading…
06:00AM
Apr-24-24 12:10PM
Apr-22-24 09:44AM
Apr-18-24 10:01AM
Apr-17-24 07:44AM
Apr-11-24 06:00AM
Apr-01-24 07:36AM
Mar-14-24 04:46PM
12:07PM
Mar-13-24 07:27PM
06:57AM
Mar-12-24 03:00PM
Feb-29-24 11:31PM
Feb-28-24 04:30PM
Feb-27-24 01:01PM
12:03AM
Loading…
Feb-23-24 12:03AM
Feb-20-24 06:00AM
Feb-19-24 09:51AM
Feb-18-24 01:26PM
Feb-16-24 10:21AM
08:38AM
Feb-15-24 11:56PM
(Thomson Reuters StreetEvents) -14.08%
07:41PM
01:34PM
10:08AM
09:30AM
08:18AM
07:10AM
07:08AM
06:18AM
(Associated Press Finance)
06:00AM
Feb-13-24 08:57AM
Feb-12-24 09:16AM
Feb-07-24 07:33PM
08:00AM
Feb-01-24 06:00AM
Jan-22-24 10:33AM
06:51AM
Jan-04-24 06:41AM
Dec-06-23 06:00AM
Dec-05-23 11:59AM
Dec-04-23 03:00PM
Nov-29-23 06:03AM
Nov-19-23 08:15AM
Nov-14-23 11:23PM
Nov-13-23 07:00AM
Nov-08-23 11:58PM
Nov-03-23 11:52AM
Nov-01-23 06:00AM
Oct-30-23 12:24PM
06:26AM
06:11AM
Oct-27-23 12:22PM
11:35AM
11:16AM
08:03AM
Oct-26-23 04:39PM
(Morningstar Research) -8.57%
10:06AM
09:30AM
09:28AM
07:15AM
06:33AM
06:08AM
(Associated Press Finance)
06:00AM
Oct-25-23 10:21AM
Oct-23-23 06:00AM
Oct-20-23 07:39AM
Oct-19-23 10:01AM
Oct-16-23 06:00AM
Oct-12-23 04:59PM
06:00AM
Oct-10-23 09:50AM
Sep-30-23 01:01PM
(Investor's Business Daily)
Sep-25-23 09:36AM
Sep-21-23 07:37PM
Sep-20-23 05:39AM
Sep-08-23 12:03PM
Sep-07-23 06:00AM
Sep-06-23 09:05AM
Aug-18-23 01:05PM
09:40AM
Aug-16-23 07:42AM
Aug-15-23 11:07AM
10:32AM
Aug-10-23 07:38PM
West Pharmaceutical Services, Inc. manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. The company was founded by Herman O. West on July 27, 1923 and is headquartered in Exton, PA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Winters Chad VP, Chief Accounting Officer Mar 11 '24 Option Exercise 173.22 675 116,924 2,124 Mar 12 11:46 AM Winters Chad VP, Chief Accounting Officer Mar 11 '24 Sale 358.82 815 292,436 1,309 Mar 12 11:46 AM Witherspoon Charles VP & Treasurer Feb 28 '24 Option Exercise 102.51 2,019 206,968 3,998 Mar 01 01:07 PM Witherspoon Charles VP & Treasurer Feb 28 '24 Sale 358.62 2,019 724,061 1,979 Mar 01 01:07 PM Green Eric Mark President, CEO and Board Chair Feb 27 '24 Option Exercise 57.38 73,132 4,196,314 217,040 Feb 29 04:35 PM Green Eric Mark President, CEO and Board Chair Feb 27 '24 Sale 359.85 64,132 23,077,971 152,908 Feb 29 04:35 PM Abraham Silji SVP, Chief Technology Officer Feb 23 '24 Option Exercise 173.22 7,012 1,214,619 11,672 Feb 27 11:37 AM Abraham Silji SVP, Chief Technology Officer Feb 23 '24 Sale 365.00 7,012 2,559,380 4,660 Feb 27 11:37 AM Winters Chad VP, Chief Accounting Officer Dec 01 '23 Option Exercise 156.18 797 124,472 2,283 Dec 05 07:33 PM Winters Chad VP, Chief Accounting Officer Dec 01 '23 Sale 349.00 1,013 353,541 1,270 Dec 05 07:33 PM Witherspoon Charles VP & Treasurer Oct 31 '23 Option Exercise 223.84 1,190 266,370 3,025 Nov 02 01:37 PM Witherspoon Charles VP & Treasurer Oct 31 '23 Sale 322.37 1,190 383,623 1,835 Nov 02 01:37 PM Favorite Annette F Sr. VP & Chief HR Officer Aug 30 '23 Option Exercise 83.47 2,000 166,940 16,877 Sep 01 03:46 PM Favorite Annette F Sr. VP & Chief HR Officer Aug 30 '23 Sale 414.64 2,000 829,277 14,877 Sep 01 03:46 PM Reiss-Clark Cindy Chief Commercial Officer Aug 22 '23 Option Exercise 263.16 3,477 915,007 7,797 Aug 24 07:24 PM Reiss-Clark Cindy Chief Commercial Officer Aug 22 '23 Sale 393.34 3,477 1,367,643 4,320 Aug 24 07:24 PM Lai Quintin J VP Strat & Investor Relations Aug 11 '23 Option Exercise 125.40 21,101 2,646,114 39,408 Aug 15 02:50 PM Lai Quintin J VP Strat & Investor Relations Aug 11 '23 Sale 395.12 21,101 8,337,487 18,307 Aug 15 02:50 PM Witherspoon Charles VP & Treasurer Aug 09 '23 Option Exercise 137.87 1,680 231,613 3,509 Aug 11 04:52 PM Witherspoon Charles VP & Treasurer Aug 09 '23 Sale 396.54 1,680 666,187 1,829 Aug 11 04:52 PM Green Eric Mark President & CEO Aug 08 '23 Option Exercise 57.38 50,000 2,869,000 184,574 Aug 10 02:50 PM Abraham Silji SVP, Chief Technology Officer Aug 08 '23 Option Exercise 102.51 8,160 836,482 12,369 Aug 10 04:31 PM Green Eric Mark President & CEO Aug 08 '23 Sale 394.77 44,000 17,369,820 140,574 Aug 10 02:50 PM Abraham Silji SVP, Chief Technology Officer Aug 08 '23 Sale 397.18 8,160 3,240,972 4,209 Aug 10 04:31 PM Birkett Bernard Sr VP, Chief Fin & Ops Off Aug 02 '23 Option Exercise 101.52 22,334 2,267,383 26,700 Aug 08 03:49 PM Birkett Bernard Sr VP, Chief Fin & Ops Off Aug 02 '23 Sale 370.39 22,334 8,272,216 4,366 Aug 08 03:49 PM Winters Chad VP, Chief Accounting Officer May 30 '23 Option Exercise 143.43 872 125,071 2,321 May 31 04:37 PM Witherspoon Charles VP & Treasurer May 30 '23 Option Exercise 102.51 1,000 102,510 2,829 May 31 04:38 PM Witherspoon Charles VP & Treasurer May 30 '23 Sale 343.05 1,000 343,050 1,829 May 31 04:38 PM Green Eric Mark President & CEO May 09 '23 Option Exercise 57.38 50,000 2,869,000 178,574 May 11 01:53 PM Green Eric Mark President & CEO May 09 '23 Sale 363.10 44,000 15,976,522 134,574 May 11 01:53 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite